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Abstract
Hand, Foot and Mouth Disease (HFMD) is a self-limiting viral disease that mainly affects infants and children. In contrast with
other HFMD causing enteroviruses, Enterovirus71 (EV71) has commonly been associated with severe clinical manifestation
leading to death. Currently, due to a lack in understanding of EV71 pathogenesis, there is no antiviral therapeutics for the
treatment of HFMD patients. Therefore the need to better understand the mechanism of EV71 pathogenesis is warranted.
We have previously reported a human colorectal adenocarcinoma cell line (HT29) based model to study the pathogenesis of
EV71. Using this system, we showed that knockdown of DGCR8, an essential cofactor for microRNAs biogenesis resulted in a
reduction of EV71 replication. We also demonstrated that there are miRNAs changes during EV71 pathogenesis and EV71
utilise host miRNAs to attenuate antiviral pathways during infection. Together, data from this study provide critical
information on the role of miRNAs during EV71 infection.
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Introduction
Hand, Foot and Mouth Disease (HFMD) is a contagious viral
disease that commonly affects infants and children, with blisters
and flu like symptoms [1–6]. HFMD is caused by a group of
enteroviruses such as enterovirus 71 (EV71) and coxsackievirus
A16 (CA16) [7–9]. However, unlike other HFMD causing
enteroviruses, EV71 is also commonly associated with severe
clinical diseases, including neurological diseases such as aseptic
meningitis, brainstem and cerebellar encephalitis leading to
cardiopulmonary failure and death [3,10–13]. Due in part to a
lack of understanding of viral pathogenesis of EV71 causing
HFMD, there are no antiviral therapies or vaccines approved by
the United States Food and Drug Administration (FDA) to prevent
HFMD infections. There is therefore a need to gain a better
understanding of the mechanism of EV71 pathogenesis. During
infection, viruses attenuate host gene expression to enhance their
survival [14–18]. Such activities include altering the cellular
microenvironment to allow successful virus replication and evasion
of the host immune system [19].
The host innate system is the first line of defence with the
interferon (IFNs) being a key component against viral infection
[17,18,20–25]. The release of IFNs begins with the recognition of
pathogen-associated molecular patterns (PAMPs) which include
Toll like receptors (TLRs), NOD like receptors (NLRs), retinoic
acid-inducible gene I (RIG-I) like receptors [24,26]. This family of
cytokines act in an autocrine and paracrine manner to induce
expression of transcription factors, gamma activated sequence and
IFN stimulated response element and the consequent induction of
IFN-stimulated genes (ISGs) which function to slow down viral
infection [20–22]. Antiviral pathways such as the programmed cell
death or apoptosis could also be activated by the host cells in
attempt to control the infection by limiting viral replication [19].
Many viruses have evolved to counteract with strategies by host
cells to establish infection. One of the mediators for such
regulation includes genes that encode for microRNA (miRNAs).
microRNAs are small single-stranded RNA species of approxi-
mately 20–24 bases in length that play a pivotal role in the post
transcriptional regulation of gene expression [27,28]. These small
RNA are first discovered in Caenorhabditis elegans but was later
discovered in a wide range of organisms from uni to multicellular
eukaryotes [29–31]. miRNAs are found to regulate many cellular
functions including cell proliferation, differentiation, homeostasis,
immune activation and apoptosis [28,29,32–34]. As such,
miRNAs can contribute to the repertoire of host-pathogen
interactions during infection by modulating and directing host
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and viral gene expression thereby playing a pivotal role during
infection. Elucidating the mechanism that the virus uses to bypass
host defence systems and establish infections will provide us with a
better understanding of the pathogenesis mechanism of the EV71
virus, allowing development of potent antiviral therapeutics for
HFMD patients.
In this study, we explore the role of miRNAs in the pathogenesis
of EV71 infected HT29 cells and identified key miRNA changes
due to EV71 infection which might play a key role during EV71
pathogenesis.
Results
We have previously reported a human colorectal adenocarci-
noma cell line (HT29) with epithelioid morphology as a useful
model to study the pathogenesis of EV71 [35]. Utilising the HT29
as a model, this study further elucidate the role of miRNAs during
EV71 infection.
Knockdown of DGCR8 resulted in the reduction of EV71
replication
In order to characterise the role of miRNAs during EV71
pathogenesis, DGCR8 was knocked down prior to infection.
HT29 cells were transfected with DsiRNA specific to DGCR8, an
essential cofactor for miRNAs biogenesis. As control, HT29 cells
were transfected with NC1, negative control duplex-scrambled
DsiRNA. Knockdown of DGCR8 was verified using qPCR
(Figure 1a). Transfection was shown to be successful using TYE
563 DS Transfection Control, fluorescent-labelled transfection
control duplex (Figure 1b).
miRNAs is essential for EV71 replication
To investigate the role of miRNAs in EV71 infection, we
compare EV71 replication in miRNAs depleted HT29 cells
against control cells (scrambled DsiRNA). Using established
protocols, the kinetics of EV71 RNA synthesis in both infected
DGCR8 knockdown cells and control cells were examined
quantitatively using real time quantitative polymerase chain
reaction (qPCR) at 36 h post infection (hpi). Interestingly, DGCR8
knockdown (miRNAs depleted) HT29 cells were unable to support
EV71 proliferation compared to control cells (Figure 2). There is a
significant decrease in viral RNA between DGCR8 knockdown
HT29 cell in contrast with control cells (scrambled DsiRNA)
(Figure 2a). Consistent with our qPCR analysis, protein analysis of
viral VP1 protein representation of EV71 replication, were shown
to be highly downregulated in EV71 infected DGCR8 knockdown
cells (Figure 2b). To further elucidate the effect of miRNAs during
EV71 infection, we asked if the host cells survivability was
enhanced in EV71 infected miRNAs depleted cells. Indeed, it was
observed that at 72 hpi, there was a statistically significant
percentage of living cells in EV71 infected DGCR8 knockdown
cells compared to control cells infected with EV71 (Figure 2c and
Figure S1). In order to validate our findings in HT29 cells, we
further test this on another colorectal cell line (RKO) and skeleton
muscle cell line (RD) where we knock down DGCR8 and examine
the effect on EV71 replication (Figure 3). Consistent with our
findings in HT29 model, EV71 is unable to establish infection in
miRNAs depleted cells (HT29, RKO and RD cells) (Figure 2 and
3).
Taken together, DGCR8 or rather miRNAs affects EV71
replication and recused its detrimental phenotype.
Identification of deregulated miRNAs during EV71
infection
To pinpoint on the differentially transcribed miRNAs used by
EV71 during infection, we perform miRNAs profiling using
Affymetrix GeneChip miRNA array. Specifically, comparative
miRNAs expression between EV71 infected cells and control non-
infected cells were performed. Microarray hybridisation identified
78 miRNAs being differentially expressed during EV71 infection
(p,0.05) (Figure 4 and Table S1). To confirm the microarray
results, relative abundance of the selected miRNAs were assayed
using qPCR. The expression pattern from 10 selected miRNAs
qPCR data showed similar direction of response in microarray
analysis data with both methodologies showing similar trends
(Figure 5 and 6). This indicates high quality and reliability of the
microarray data analysis.
EV71 down regulate host immune system using host
miRNAs during infection
To understand why miRNAs depleted cells resulted in the
inability of EV71 to established infection; we examine the
expression of 84 key genes involved in the innate antiviral immune
response between EV71 infected miRNAs depleted HT29 cells in
comparison with control cells (scrambled DsiRNA). In particular,
we examine the host antiviral expression profile between infected
DGCR8 knockdown cells against control cells. Using qPCR,
quantitative expression of 52 antiviral genes from various antiviral
signalling pathways such as Toll-like receptor signalling, Nod-like
receptor signalling, RIG-1-like receptor signalling and type 1
interferon signalling were statistically up regulated in DGCR8
knockdown cells (Figure 7a, 7b, 7c, 7d). Noteworthy, CASP1,
OAS2, DDX58, DHX58, CCL5, CXCL10, CXCL11, IRF7,
IFBB1, ISG15, MX1 and STAT1 have at least 10–550 fold
increase (Figure 7a, 7b, 7c, 7d).
Discussion
Viruses have developed highly sophisticated gene-silencing
mechanisms to evade host-immune response in order to establish
infection. One of such mediators used by viruses is miRNAs.
miRNAs is a new paradigm of RNA-directed gene expression
regulation which contribute to the repertoire of host-pathogen
interactions during viral infection. Cellular miRNAs could be
involved during viral infection with either positive or negative
effects on viral replication kinetics [36,37]. Indeed, computational
prediction reveal that one miRNAs may regulate hundreds of
genes while one gene may be in turn regulated by hundreds of
miRNAs [38]. However, the role of cellular miRNAs in the
defence against viral infection has thus remained elusive. Given
the scope of miRNA-mediated gene regulation in the mammalian
system, cellular miRNAs may directly or indirectly affect virus
pathogenesis. Cellular miRNA expression could be remodelled by
viral infection, which can alter the host cellular microenvironment
and attributing to both host antiviral defence and viral factors
[25,32,36,39,40].
The biogenesis of miRNAs begins with the transcription of a
long primary transcript known as pri-miRNA by RNA polymerase
II [27–29,32,39,41]. Pri-miRNAs are cleaved/processed by
Figure 1. Knockdown of DGCR8 using DsiRNA. (A) Relative expression of DGCR8 gene measured by qPCR verifying knockdown. (n = 3, **** = p
values of ,0.0001) (B) Transfection Control using fluorescent-labeled transfection control duplex TYE 563 DS to monitor transfection efficiency.
doi:10.1371/journal.pone.0102997.g001
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RNase III enzyme (Drosha), double-stranded-RNA-binding pro-
tein, (DiGeorge Syndrome Critical Region; DGCR8) and RNAse
III-like Dicer to become functional miRNAs. In this study, we
have demonstrated that abolishing functional miRNAs in human
epithelial colorectal cell line (HT29) impair EV71 replication while
this was not observed in control cells treated with scrambled
DsiRNA. On the contrary, global knockdown of miRNAs have
been previously shown to have enhance HIV-1 infection [42,43].
Knock down of DGCR8, a precursor to miRNAs biogensis were
shown to enhance human immunodeficiency virus (HIV) replica-
tion [42,43]. This implies that EV71 utilise miRNAs during
infection and in the absent of miRNAs, EV71 was unable to
successfully mount the infection.
Another study reported by Otsuka and colleagues showed a
similar finding in Vesicular stomatitis virus (VSV) infection [44].
Otsuka and colleagues observed that impaired miRNA production
in mice with dicer deficient mice resulted in the hypersensitivity
toward infection by VSV [44]. It was observed there is no
alternation of interferon-mediated antiviral response by dicer
deficiency instead the change in virus replication is due to miR-24
and miR-93 [44]. Otsuka and colleagues shown that miR-24 and
miR-93 could target VSV viral protein and thus in miRNA
depleted cells, VSV replication was enhanced in the absence of
miR-24 and miR-93 [44].
In recent years, there are reported evidences of specific host-
cellular miRNAs modulating host-pathogen interaction [44–51].
Cytomegalovirus (CMV) for example was observed to down
regulate miR-27a [45]. Overexpression of miR-27a using miRNAs
mimics was shown to inhibit CMV proliferation and virus titres
suggesting that miR-27a or miR-27a-regulated genes plays a role
during CMV infection [45,52]. Hepatitis C virus (HCV), an
enveloped RNA virus of the Flavivirus family, responsible for both
acute and chronic hepatitis in humans induced a liver-specific
cellular miRNA, miR-122 for the facilitation of HCV replication
[17,48,51,53–55]. It was suggested that miR-122 is a valuable
target for antiviral intervention and therapeutics. In vivo
treatment of HCV-infected chimpanzees with antisense miR-122
successfully reduced HCV virus titres demonstrating promising
antiviral treatment against virus induced diseases [48,49,53,54].
Indeed, various miRNAs have been identified to play a role
during EV71 pathogenesis. Recent publications of investigations
into the role of miRNA in enterovirus infection have reported that
enterovirus-induced miRNAs such as miR-23b, miR-296-5p,
miR-141 and miR-146a play a role in EV71 replication [8,56–
58]. The use of miRNA inhibitors or mimics have demonstrated
that miRNAs plays an important role in EV71 pathogenesis.
miRNA inhibitors or mimics on these miRNAs either inhibited or
enhanced EV71 replication during infection.
In particular, our results revealed miR-548 to be significantly up
regulated in EV71 infected cells at 36 hpi in comparison with
control non infected cells. Further bioinformatics analysis revealed
that miR-548 was involved in antiviral response during infection
[17,23,25,38,59]. Consistent with our findings, Li and colleagues
have recently identified the involvement of miR-548 in IFN
signalling pathways during viral infection [59]. Li and colleagues
demonstrated that miR-548 down-regulates host antiviral response
via direct targeting of IFN-l1 [59]. In contrast, in EV71 infected
rhabdomyosarcoma (RD) cells, miR-548 was observed to decrease
in a time dependent manner [59]. In view that the host innate
system is the first line of defence with IFNs being a key player
during viral infection, it is atypical that miR-548 was up regulated
to down regulate the host immune system [17,18,20–25]. The use
of miR-548 mimics and inhibitors were shown to enhance or
inhibit EV71 replication in RD cells respectively [59].
The innate immune system has evolved an arsenal of
mechanism to sense and destroy invading pathogen. An interesting
question that arises is whether EV71 is able to regulate host
cellular miRNA transcription and processing during infection
thereby leading to the down-regulation of deleterious cellular
miRNA and/or the up-regulation of advantageous cellular
miRNAs to enhance its replication in the host cells. To add to
this intriguing interplay between cellular miRNAs and viral
pathogens, Huang and colleagues has demonstrated that HIV, an
enveloped RNA virus of the Retreoviridae family utilise host
cellular miR-28, miR-125b, miR-150, miR-223 and miR-382 to
control viral protein synthesis in order to evade host immune
system [47]. Epstein-Barr virus (EBV), a DNA virus of the Herpes
family, for example induce the expression of miR-29b, miR-155
and miR-146a to mediate the down regulation of innate immune
response and IFN signalling pathways to enhances its survival
[46,60,61]. Lecellier and colleagues have shown that in primate
foamy virus type 1 (PFV-1), overexpression of cellular miRNA
miR-32 could induce an antiviral response to inhibit virus
replication [37].
To test this reasoning that EV71 down regulate host miRNAs
during infection to enhance its survival, we next ask if the innate
response and signalling pathways were altered in EV71 infected
miRNA-depleted cells. Therefore, we analysed the expression of
84 key genes involved in the innate antiviral immune response
between EV71 infected miRNAs depleted HT29 cells in
comparison with control cells (scrambled DsiRNA). Quantitative
analysis\revealed 52 antiviral genes from various antiviral
signalling pathways such as Toll-like receptor signalling, Nod-like
receptor signalling, RIG-1-like receptor signalling and type 1
interferon signalling were significantly up regulated in EV71
infected miRNAs depleted HT29 cells. In particular, CASP1,
OAS2, DDX58, DHX58, CCL5, CXCL10, CXCL11, IRF7,
IFBB1, ISG15, MX1 and STAT1 have at least 10–550 fold
increase. The enhanced host antiviral response in miRNA-
depleted cells during EV71 infection may result in the inability
for EV71 to replicate during infection (Figure 8).
The host immune response is responsible for the eradication of
invading pathogens, as such viruses has developed means to
counteract with the induction, signalling and antiviral pathways
[16,20,21,25,40]. RNA viruses generally block and inhibit IFN
and antiviral molecules detrimental to virus replication [20,24].
Despite all the sophisticated mechanism used by viruses to inhibit
host immune system, host has been under evolutionary pressure
against viral antagonism of IFN system [20,21,24,40]. Our result
suggests that EV71 attenuate host miRNAs to mediate host
immune system during infection (Figure 8). As a result of DGCR8
knockdown, EV71 is unable to regulate host miRNAs to enhance
cellular microenvironment leading to the inability to establish
infection (Figure 8). Notwithstanding, IFN signalling pathways
Figure 2. miRNA depleted HT29 cells is not able to support EV71 replication. DGCR8 knockdown HT29 cells and control HT29 cells
(scrambled DsiRNA) were infected with EV71 (MOI of 1). Total intracellular RNA were harvested at 36 hpi, converted to cDNA and measured by qPCR
with primers specific to viral VP1. Total intracellular protein were harvested at at 36 hpi and measured by western blot (A) Relative expression of EV71
viral RNA measured by qPCR. (n = 3, **** = p values of,0.0001) (B) Western blot analysis for EV71 VP1 viral protein. (C) Cell viability assessed at 72 hpi
using vital dye trypan blue. (n = 3, ** = p values of ,0.01).
doi:10.1371/journal.pone.0102997.g002
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such as type I interferon was previously demonstrated to play an
important role during EV71 pathogenesis [62,63]. These results
warrant further studies for the identification of specific miRNAs
which play a pivotal role during EV71 pathogenesis specifically
targeting the host antiviral signalling pathway.
Conclusion
In conclusion, we provided evidence for an intricate physiolog-
ical interplay between host miRNAs machinery and invading
pathogen, EV71. We reported three salient findings. First,
DGCR8, an essential cofactor for microRNAs biogenesis contrib-
ute to a central role during EV71 pathogenesis. We have shown
that EV71 is not able to replicate efficiently in miRNAs depleted
cells. Secondly, our results suggest that EV71 may remodel the
cellular miRNAs composition thereby utilising the host cellular
miRNAs to enhance cellular microenvironment for viral replica-
tion. Specifically, our result suggests that EV71 may be at least
partially responsible for the up regulation of host miR-548 to
enhance cellular microenvironment for viral replication. Thirdly,
remodelling of miRNAs during EV71 infection plays a significant
role specifically in antiviral response. We have demonstrated that
in EV71 infected miRNAs depleted cells, host antiviral responses
from various antiviral signalling pathways such as Toll-like
receptor signalling, Nod-like receptor signalling, RIG-1-like
receptor signalling and type 1 interferon signalling were signif-
icantly higher in comparison with EV71 infected control cells.
This may explain our result on the inability for EV71 to infect
miRNAs depleted cells given the enhanced host antiviral response.
Taken together, our study has provide valuable knowledge toward
the study of host-pathogen interaction during EV71 pathogenesis
and this could lead to future investigation for the development of
Figure 3. EV71 is unable to establish infection in both RKO and RD miRNAs depleted cells. DGCR8 knockdown cells and control cells
(scrambled DsiRNA) in both RKO and RD cell line were infected with EV71 (MOI of 1). Total intracellular RNA were harvested at 12 hpi, converted to
cDNA and measured by qPCR with primers specific to viral VP1. (A) Relative expression of DGCR8 gene in miRNAs depleted RKO cells measured by
qPCR verifying knockdown. (n = 3, * = p values of ,0.05) (B) Relative expression of DGCR8 gene in miRNAs depleted RD cells measured by qPCR
verifying knockdown. (n = 3, * = p values of ,0.05) (C) Relative expression of EV71 viral RNA in miRNAs depleted RKO cells measured by qPCR. (n = 3,
* = p values of ,0.05) (D) Relative expression of EV71 viral RNA in miRNAs depleted RKO cells measured by qPCR. (n = 3, * = p values of ,0.05).
doi:10.1371/journal.pone.0102997.g003
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antiviral therapeutics using miRNAs inhibitors against EV71. This
will open the door toward novel host-defence mechanism that
exists in mammalian cells as well as to the antiviral mechanisms
employed during EV71 pathogenesis.
Materials and Methods
Cell culture and virus propagation
The EV71 strain used in this study was isolated from a fatal case
of HFMD during October 2000 outbreak in Singapore, Entero-
virus 5865/sin/000009 strain from subgenogroup B4 (accession
number 316321; hereby designated as Strain 41) (a gift from Mrs
Phoon Meng Chee, Department of Microbiology, National
University of Singapore). Human colorectal cell line (HT29)
(ATCC catalog no. HTB-38) was maintained in Roswell Park
Memorial Institute medium (RPMI) (PAA Laboratories, Austria)
supplemented with 10% (v/v) Fetal Bovine Serum (FBS) (PAA
Laboratories, Austria) and 2% penicillin–streptomycin (PAA
Laboratories, Austria) at 37uC with 5% CO2. Human skeleton
muscle cell line (RD) (ATCC catalog no. CCL-136) and Human
colorectal cell line (RKO) (ATCC catalog no. CRL-2577) were
maintained in Eagle’s minimum essential medium (EMEM) (PAA
Laboratories, Austria) supplemented with 10% (v/v) Fetal Bovine
Serum (FBS) (PAA Laboratories, Austria) and 2% penicillin–
streptomycin (PAA Laboratories, Austria) at 37uC with 5% CO2.
The virus stock was prepared by propagation of viruses using 90%
confluent HT29 cells monolayer in RPMI with 10% FBS at 37uC
with 5% CO2. The virus titres were determined using 50% tissue
culture infective dose (TCID50) per millilitre (mL) according to
Reed and Muench method [64].
DsiRNA transfection and EV71 infection
HT29, RD and RKO cells were seeded at a concentration of
26105 cells/ml in 6-well plates and incubated for 8 h at 37uC with
5% CO2. Cells were washed twice with phosphate buffered saline
(PBS) and transfected using Lipofectamine RNAiMAX (Invitrogen
Corporation, CA, USA) with TriFECTa Dicer-Substrate RNAi
KIT (Integrated DNA Technology, Coralville, IA, USA). Briefly,
10 nM of DGCR8 DsiRNA (NM_001190326 duplex 2), NC1,
negative control duplex-scrambled DsiRNA (NM_001190326)
and TYE 563 DS Transfection Control, fluorescent-labeled
transfection control duplex (NM_001190326) were used to
transfect the cells respectively (Integrated DNA Technology,
Coralville, IA, USA). Following 24 h after transfection, cells were
washed twice with PBS and infected with EV71 at multiplicity of
infection (MOI) of 1. The culture media were removed and
replaced with 2 mL of fresh RPMI medium after 1 h of incubation
at 37uC with 5% CO2.
EV71 infection for miRNA profiling
HT29 cells were seeded at a concentration of 56105 cells/ml in
6-well plates and incubated for 24 h at 37uC with 5% CO2. Cells
were washed twice with phosphate buffered saline (PBS) and
infected with EV71 at multiplicity of infection (MOI) of 1 or nil
respectively. The culture media were removed and replaced with
2 mL of fresh RPMI medium after 1 h of incubation at 37uC with
5% CO2.
Total cellular RNA extraction
The respective infected cells were harvest at 12 or 36 hours
posts infection (hpi) respectively. The total cellular RNA of HT29,
Figure 4. Heat map of the microarray miRNA expression profile of EV71 infected and non-infected control colorectal cells, HT29.
The two-way hierarchical cluster heat map showed differential expressed miRNAs of two groups of samples. The miRNAs were chosen according to
the cut off p,0.05 where blue represents miRNAs with decreased expression and red represent miRNAs with increased expression. (n = 3, * = p values
of ,0.05).
doi:10.1371/journal.pone.0102997.g004
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RD and RKO cells were extracted using the miRNeasy mini kit
(Qiagen, Hilden, Germany) in accordance to the manufacturer’s
instructions. Briefly, the cells were lysed and homogenise using
lyses solution provided (Qiagen, Hilden, Germany). Total RNA
were harvested using the RNeasy spin column and wash twice
before elution (Qiagen, Hilden, Germany). Harvested total RNA
was quantitated using Nanodrop 100 spectrophotometer (Ther-
moScientific, Waltham, USA).
miRNA microarray analysis
The extracted total RNA was labelled with FlashTag Biotin
HSR RNA Labeling Kits for the Affymetrix GeneChip miRNA
array according to manufacturer’s instruction. Briefly, one
microgram of total RNA will be incubated with ATP and Poly
A polymerase at 37uC for 15 m to add a 39 polyA tail. A ligation
reaction will then be performed to covalently attach to the miRNA
population a multiple-biotin molecule containing a 3DNA
dendrimer. Labelled samples will subsequently be processed
according to manufacturer’s instructions for the Affymetrix
miRNA Array 2.0 (Affymetrix, Santa Clara, CA). After hybrid-
isation for 16 h at 48uC, the arrays will be washed and stained in
an Affymetrix Fluidics station 450, then scanned in an Affymetrix
Figure 5. Validation of differential expression of selected miRNAs by qPCR. Ten expression levels of selected miRNAs from microarray assay
were validated using qPCR. U6snRNA was used as reference RNA for the normalization of miRNAs and relative gene expression was quantified based
on 22DDCT. (n = 3, * = p values of ,0.05).
doi:10.1371/journal.pone.0102997.g005
Figure 6. Heat map of differential expression of selected
miRNAs by microarray. The two-way hierarchical cluster heat map
showed differential expressed selected miRNAs of two groups of
samples. The miRNAs from both methodology qPCR data showed
similar direction of response in microarray analysis data with both
methodologies showing similar trends where blue represents miRNAs
with decreased expression and red represent miRNAs with increased
expression.
doi:10.1371/journal.pone.0102997.g006
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3000 7G scanner. Raw data for the microarray (GSE57372) was
analysed with Partek Genomics Suite (Partek Incorporated, Saint
Louis, USA) where p,0.05 is considered significant.
cDNA synthesis
For the conversion of mRNA to cDNA, 1 mg of the total RNA
was reverse transcripted using RT2 First Strand kit (Qiagen,
Hilden, Germany) in accordance to the manufacturer’s instruc-
tions. Briefly, 1 mg of the extracted RNA was first mixed with
Buffer GE to a total volume of 10 ml for genomic DNA elimination
and incubated at 42uC for 5 m and on ice for 1 m. Reverse-
transcription mix which consist of enzyme reverse transcriptase
and buffer was then added to a volume of 20 ml and subjected to
thermal profile of 42uC for 15 m followed by 95uC for 5 m. 91 ml
of RNase free water was then added to each reaction in
accordance to the manufacturer’s instructions.
For conversion of microRNA to cDNA, 10 ng of the total RNA
was reverse transcripted using the Universal cDNA Synthesis kit
(Exiqon, Denmark) the manufacturer’s instructions. Briefly, 10 ng
of the extracted RNA will be mixed with enzyme reverse
transcriptase and buffer to a volume of 10 ml. The reaction mix
will then subject to thermal profile of 25uC for 5 m, 42uC for 30 m
followed by 85uC for 5 m according to the manufacturer’s
instructions.
Quantitative real time polymerase chain reaction
The EV71 specific primers targeting the conserve VP1 regions
were 59-GCTCTATAGGAGATAGTGTGAGTAGGG-39 and
the reverse primer 59-ATGACTGCTCACCTGCGTGTT-39
[65]. Primers for DGCR8 were 59-ACTTGTGCATGT-
TAGCTGTGTAGA-39 and the reverse primer 59-GCTTAA-
GACTAGTTTACAAGACCAGAGT-39 were designed to span
exon-exon boundaries. The primers for the house keeping gene
actin (b-ACT) used were 59-ACCAACTGGGACGACATGGA-
GAAA-39 and the reverse primer 59-TAGCACAGCCTGGA-
TAGCAACGTA-39. The qPCR was performed using the iTaq
Universal SYBR Green Supermix (Bio-Rad Laboratories, CA,
USA) on the BioRad CFX96 Real-Time PCR system (Bio-Rad
Laboratories, CA, USA). Briefly, 1 ml of cDNA and 1 ml of the
forward and the reverse primers were added iTaq Universal
SYBR Green Supermix. The reaction mix was then subjected to
thermal profile of denaturation at 95uC for 30 s, followed by
amplification and quantification in 40 cycles at 95uC for 5 s
followed by 60uC for 30 s. At the end of amplification cycles,
melting temperature analysis was performed by the BioRad
Figure 7. EV71 is unable to down regulate host antiviral response in miRNA depleted cells during infection. DGCR8 knockdown cells
and control cells (scrambled DsiRNA) were infected with EV71 (MOI of 1). Total intracellular RNA were harvested at 36 hpi, converted to cDNA and
measured by quantitative real time polymerase chain reaction (qPCR) (n = 3, * = p values of ,0.05). A) Relative expression of Toll-like receptor
signalling measured by qPCR. (B) Relative expression of RIG-1 like receptor signalling measured by qPCR. (C) Relative expression of Nod-like receptor
signalling measured by qPCR. (D) Relative expression of Type 1 interferon signalling measured by qPCR.
doi:10.1371/journal.pone.0102997.g007
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CFX96 Real-Time PCR system (Bio-Rad Laboratories, CA,
USA). Relative gene expression was quantified based on 22DDCT
method [66].
For RT2 profiler PCR array, PCR arrays were performed with
customized PCR containing pre-dispensed primers to monitor
Human antiviral response PAHS-122ZD-2 (Qiagen, Hilden,
Germany). qPCR was performed using RT2 SYBR Green qPCR
mastermix (Qiagen, Hilden, Germany). Briefly, a total volume of
25 ml of cDNA and RT2 SYBR Green qPCR mastermix were
added into each well of the Human antiviral response array 96
wells plate PAHS-122ZD-2 (Qiagen, Hilden, Germany) in
accordance to the manufacturer’s instructions. The reaction mix
was then subjected to thermal profile of denaturation at 95uC for
10 m, followed by amplification and quantification in 40 cycles at
95uC for 15 s followed by 60uC for 1 m. At the end of
amplification cycles, melting temperature analysis was performed
by the BioRad CFX96 Real-Time PCR system (Bio-Rad
Laboratories, CA, USA).
For the detection of microRNA, qPCR was performed using the
ExiLENT SYBR Green Master mix (Exiqon, Denmark) on the
BioRad CFX96 Real-Time PCR system (Bio-Rad Laboratories,
CA, USA). Briefly, 2.5 ml of cDNA and 1 ml of the forward and the
reverse primers was added to ExiLENT SYBR Green Master mix
(Exiqon, Denmark) according to the manufacturer’s instructions.
The reaction mix will then subjected to thermal profile of
denaturation at 95uC for 10 m, followed by amplification and
quantification in 40 cycles at 95uC for 10 s, 60uC for 30 s followed
by 50uC for 30 s. At the end of amplification cycles, melting
temperature analysis will be performed by the BioRad CFX96
Real-Time PCR system (Bio-Rad Laboratories, CA, USA).
Primers for microRNA qPCR were designed and purchased from
Exiqon, Denmark. U6snRNA was used as reference RNA for the
normalization of microRNA (miRNA) qPCR data. Relative gene
expression was quantified based on 22DDCT method [66].
Western blot
Total cellular protein for HT29 cells and control cells were
collected using a lysis mix in mammalian cell lysis solution–
CelLytic M (Sigma-Aldrich Pte Ltd, USA) in accordance with
manufacturer’s instructions. Equal protein concentration (20 mg)
from each samples were added onto 10% Mini-PROTEAN TGX
(Bio-Rad Laboratories, CA, USA) and separated by electropho-
resis. Separated proteins were transferred onto nitrocellulose
membrane (Bio-Rad Laboratories, CA, USA). The membranes
were incubated with mouse anti EV71 antibody (AbD serotech,
Oxford, UK) or anti tubulin antibody (Santa Cruz Biotechnology
inc, California, USA) respectively in shaker 4uC overnight. The
membranes were washed three times in Tris-buffered saline with
0.05% tween-20 before and incubating with secondary antibodies
conjugated to horseradish peroxidase (HRP) for 30 m. (Thermo-
Scientific, Waltham, USA). After three wash with Tris-buffered
saline and 0.05% tween-20, membrane was subjected to Clarity
Western ECL Substrate (Bio-Rad Laboratories, CA, USA) in
accordance with manufacturer’s instructions. The membranes
Figure 8. Schematic illustration of the interplay between EV71 and host miRNAs. EV71 altered host miRNAs such as has-miR-548 to
manipulate host antiviral responses such as Toll-like signalling, NOD-like signalling, RIG-1 signalling and Type I interferon pathways to enhance its
survival during pathogenesis.
doi:10.1371/journal.pone.0102997.g008
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were then scanned using the LI-COR C-DiGit Blot Scanner (LI-
COR Biosciences, Lincoln, Nebraska, USA).
Cell viability and counts
Cell count and viability was performed at 0 h, 48 h and 72 h on
the Luna Automated Cell Counter system (Logos Biosystem, USA)
in accordance to the manufacturer’s instructions. Briefly, the cells
were trypsinised and topped up with fresh media to a total volume
of 1000 ml of media and 10 ml of this cell suspension were mixed
with 10 ml of tryphan blue. 10 ml of this diluted cell suspension
were then loaded onto the Luna counting slide for analysis.
Statistical analysis
All statistical analysis was performed on GraphPad Prism
Version 6.0c (GraphPad Software, USA). Student t test was used
to compare two groups. p values of ,0.05 were considered
statistically significant.
Supporting Information
Figure S1 Cell viability assessed 24 h after transfection
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